This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabolic outcomes. In addition, the study describes an accelerated and assorted pipeline of drugs that are not GLP-1 based, demonstrating new delivery options and a rapidly evolving digital health component of personalized care.

The study identifies leading growth drivers, such as significant spending by pharmaceutical giants, the emergence of online health platforms, and increasing customer demand for personalized interventions. At the same time, it identifies undeniable restraints, including price competition from generics, barriers associated with patient adherence, and the high cost of R&D. The study also outlines the clinical trial landscape and provides insight into the strategic direction of major companies and the aggressive timelines presented by regulators.

Finally, the study identifies 3 important growth opportunities: GLP-1-based multi-agonists; advanced delivery formats; and integration with digital health and personalized care, each offering distinct channels for growth, expanded patient outcomes, and market opportunities. This Strategic Intelligence aims to provide stakeholders with insights to keep pace with this evolving market and its increasing opportunities for transformational growth.